Stockscreener 앱 받기
2.90
0.69%
0.02
시간 외 거래:
2.90
Atea Pharmaceuticals Inc 주식(AVIR)의 최신 뉴스
Atea Pharmaceuticals board nominee withdrawal ahead of 2025 meeting By Investing.com - Investing.com South Africa
Atea Pharmaceuticals board nominee withdrawal ahead of 2025 meeting - Investing.com
Driver Notifies Atea Pharmaceuticals of Withdrawal of Notice of Nomination - The Manila Times
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
Charles Schwab Investment Management Inc. Boosts Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals takes steps to boost shareholder value By Investing.com - Investing.com South Africa
Atea Pharmaceuticals takes steps to boost shareholder value - Investing.com
Atea Pharma Reviewing Strategic Opportunities After Cutting 25% of Jobs - MarketWatch
Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value - GlobeNewswire
Atea's Bold Restructuring: $15M Cost Savings Plan and Strategic Review Unveiled - Stock Titan
Atea Shareholder Seeks Board Change, Plans to Nominate Directors at 2025 Annual Meeting - Marketscreener.com
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors - MarketScreener
Connor Clark & Lunn Investment Management Ltd. Raises Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals Issues Statement Regarding Director Nominations - GlobeNewswire
Atea Pharmaceuticals receives notice of director nominations from Bradley Radoff -March 21, 2025 at 05:58 pm EDT - MarketScreener
Major Shake-up Looms: Activist Investor Challenges Atea Pharmaceuticals Board Control - StockTitan
Atea Pharmaceuticals, Inc. (AVIR): A Bull Case Theory - Insider Monkey
Atea Pharmaceuticals Announces Presentation of - GlobeNewswire
Major Breakthrough: Atea's New Hepatitis C Drug Enters Final Testing with Shorter Treatment Time - StockTitan
Earnings call transcript: Atea Pharmaceuticals Q4 2024 results weigh on stock - Investing.com Australia
What is William Blair’s Forecast for AVIR Q1 Earnings? - Defense World
William Blair Reaffirms “Outperform” Rating for Atea Pharmaceuticals (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals Faces Challenges Amid Workforce Reductions and Cost-Cutting Efforts - MSN
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2024 Earnings Call Transcript - Insider Monkey
BML Capital Management LLC Has $25.49 Million Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - MarketBeat
Atea Pharmaceuticals’ Promising Earnings Call Highlights - TipRanks
Atea Pharma Cuts Workforce By 25%, Expects $15 Million In Cost Savings, Plans Phase 3 Hepatitis C Trial - Benzinga
Atea Pharmaceuticals Advances HCV Program with FDA Approval - TipRanks
Atea Pharmaceuticals Cuts Workforce by 25% - MarketWatch
Atea Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Atea Pharmaceuticals reports Q4 EPS (40c), consensus (29c) - TipRanks
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides - The Bakersfield Californian
Can Atea's 98% Effective HCV Drug Reshape the $3B Market? FDA Says Yes to Phase 3 - StockTitan
Atea Pharmaceuticals (AVIR) Expected to Announce Quarterly Earnings on Thursday - Defense World
AVIRAtea Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025 - GlobeNewswire
Atea Pharmaceuticals to Host Conference Call on Q4 and Full Year 2024 Financial Results - Nasdaq
When Will Atea Pharmaceuticals Reveal Its Antiviral Pipeline Progress? Key Date for Biotech Investors - StockTitan
Atea Pharmaceuticals Appoints Arthur Kirsch as Class I Director Amid Voting Agreement Disclosure - Defense World
Atea Pharmaceuticals appoints Arthur Kirsch to Board By Investing.com - Investing.com Canada
Atea Pharmaceuticals Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
Atea Pharmaceuticals Appoints Arthur Kirsch as Director - TipRanks
Atea Pharmaceuticals appoints new board member By Investing.com - Investing.com Canada
Atea Pharmaceuticals appoints new board member - Investing.com India
Atea Pharmaceuticals appoints Arthur Kirsch to Board - Investing.com India
1.23%
1.63%
자본화:
|
볼륨(24시간):